Saturday 17 October 2026
Export KALA’s income statement to Excel — free account
KALA BIO, Inc.
KALA Healthcare Biotechnology
KALA BIO, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.9 million. In the quarter to June 2026, EPS grew 75.1% and free cash flow grew 80.2%, each against the same quarter a year earlier.
0.19
0.00
0.00%
Follow KALA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
3,969.10% | (279.20%) | (238.69%) | (345.32%) | |
| (90.62%) | (83.05%) | (64.90%) | (43.23%) | ||
ROIC |
0.00% | 0.00% | (948.11%) | (722.69%) | |
Return on Tangible Assets |
465.65% | (385.65%) | (182.64%) | (111.46%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(228.86) | (196.88) | (2.19) | (267.70) | |
Free Cash Flow |
(32.22) | (32.09) | (26.06) | (19.86) | |
Capital Expenditures |
(0.19) | (0.10) | — | — | |
| Other line items | |||||
Cash ROIC |
(78.90%) | (220.51%) | (133.48%) | (122.06%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(8.48) | (11.95) | — | — | |
Operating CF/Net income |
0.89 | 1.19 | 1.33 | 1.97 | |
Depreciation/Fixed assets |
1.83 | 0.00 | — | — | |
Capex/Depreciation |
(0.17) | 0.29 | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(227.51) | (196.26) | (2.19) | (267.70) | |
Capex per Share |
(1.35) | (0.61) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates